CLINDAMYCIN LU clindamycin (as hydrochloride) 150 mg hard capsules blister pack

Active ingredient:

clindamycin hydrochloride, Quantity: 162.868 mg

Available from:

Luminarie Pty Ltd

INN (International Name):

clindamycin hydrochloride

Pharmaceutical form:

Capsule, hard

Composition:

Excipient Ingredients: lactose; purified talc; microcrystalline cellulose; povidone; magnesium stearate; sodium starch glycollate; titanium dioxide; brilliant blue FCF; purified water; Gelatin; sodium lauryl sulfate; tartrazine; propylene glycol; ethanol; isopropyl alcohol; Shellac; tert-butyl alcohol; sodium hydroxide

Administration route:

Oral

Units in package:

100, 50, 24

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

CLINDAMYCIN LU (clindamycin hydrochloride) capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.,CLINDAMYCIN LU capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci.,Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate.,Anaerobes:,Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and skin structure infections, septicaemia,Staphylococci: Serious respiratory tract infections; serious skin and skin structure infections; septicaemia; acute haematogenous osteomyelitis,Pneumococci: Serious respiratory tract infections,Adjunctive Therapy: In the surgical treatment of chronic bone and joint infections due to susceptible organisms. Indicated surgical procedures should be performed in conjunction with antibiotic therapy.,Bacteriological studies should be performed to determine the causative organisms and their susceptibility to clindamycin.

Product summary:

Visual Identification: No. 2 apple green capsule and imprinted with CLD 150; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Authorization status:

Registered

Authorization date:

2014-08-18